Equities research analysts expect that Sientra, Inc. (NASDAQ:SIEN) will announce sales of $16.13 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sientra’s earnings, with estimates ranging from $15.50 million to $16.60 million. Sientra reported sales of $23.21 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 30.5%. The firm is expected to report its next quarterly earnings results on Wednesday, March 10th.
On average, analysts expect that Sientra will report full year sales of $64.73 million for the current fiscal year, with estimates ranging from $64.10 million to $65.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $81.70 million, with estimates ranging from $80.00 million to $83.90 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Sientra.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Monday, November 9th. The medical instruments supplier reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.26. Sientra had a negative net margin of 140.76% and a negative return on equity of 130.33%. The company had revenue of $19.22 million for the quarter, compared to analyst estimates of $13.83 million.
SIEN has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. William Blair reiterated an “outperform” rating on shares of Sientra in a research report on Tuesday, November 10th. Finally, SVB Leerink boosted their target price on shares of Sientra from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Tuesday, November 10th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $6.75.
Shares of NASDAQ:SIEN traded down $0.07 during trading on Thursday, reaching $3.89. The stock had a trading volume of 467,918 shares, compared to its average volume of 1,098,895. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.95 and a current ratio of 2.85. Sientra has a 52 week low of $1.00 and a 52 week high of $9.71. The firm’s fifty day moving average is $4.69 and its 200 day moving average is $4.13. The stock has a market cap of $196.27 million, a price-to-earnings ratio of -1.84 and a beta of 1.36.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC raised its holdings in Sientra by 370.7% during the third quarter. Squarepoint Ops LLC now owns 258,543 shares of the medical instruments supplier’s stock worth $879,000 after buying an additional 203,620 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Sientra by 22.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 112,335 shares of the medical instruments supplier’s stock valued at $435,000 after purchasing an additional 20,527 shares during the last quarter. Baird Financial Group Inc. purchased a new stake in shares of Sientra in the second quarter valued at about $1,411,000. Bank of America Corp DE raised its holdings in shares of Sientra by 9.1% in the second quarter. Bank of America Corp DE now owns 42,050 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 3,511 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Sientra in the second quarter valued at about $41,000. Hedge funds and other institutional investors own 76.86% of the company’s stock.
About Sientra
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: What is a Tariff?
Get a free copy of the Zacks research report on Sientra (SIEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
